Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerenis names Richard Pasternak chair

This article was originally published in Scrip

Executive Summary

Cerenis Therapeutics, a biopharmaceutical company developing an engineered human apoA-I-containing pre-β HDL mimetic for the treatment of cardiovascular disease, has appointed Dr Richard C Pasternak chair of the board of directors.  He succeeds Dr Jean-Pierre Garnier, who is stepping down from the company for personal reasons. Dr Pasternak has spent the last 35 years as an academic and biopharmaceutical clinician-scientist, with a long-standing research interest in vascular disease, lipid disorders and atherosclerosis, as well as prevention and patterns of practice and disease management. He has been a non-executive director on Cerenis' board since November 2011.

You may also be interested in...



Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Execs On The Move, Sep 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Snapshot: September Highlights

A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel